Le médicament du mois. L'association calcipotriol-dipropionate de bétamethasone (dovobet).

Administration, Topical; Betamethasone/administration & dosage/analogs & derivatives/therapeutic use; Calcitriol/administration & dosage/analogs & derivatives/therapeutic use; Drug Therapy, Combination; Humans; Inflammation; Psoriasis/drug therapy

Abstract :

[en] The topical treatment of psoriasis benefits from the alternate use of dermocorticosteroids and vitamin D3 analogues. A new galenic formulation allows to combine them in a single application. Dovobet (LEO Pharma) ointment is the association of calcipotriol 50 microg/g with betamethasone dipoprionate 0.5 mg/g. This formulation boosts the therapeutic activity of calcipotriol. It also decreases the irritative inflammatory reaction due to calcipotriol without increasing the atrophogenic risk of the dermocorticoid.

Disciplines :

Dermatology

Author, co-author :

Henry, Frédérique ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Flagothier, Caroline ; Centre Hospitalier Universitaire de Liège - CHU > Dermatologie

Delvoye, Pierre; Centre Hospitalier Régional de Huy > Dermatologie

Pierard, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

French

Title :

Le médicament du mois. L'association calcipotriol-dipropionate de bétamethasone (dovobet).

Alternative titles :

[en] The calcipotriol-betamethasone dipropionate association.

Publication date :

2005

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

893-5

Peer reviewed :

Peer reviewed

Available on ORBi :

since 23 March 2009

Statistics

Number of views

250 (4 by ULiège)

Number of downloads

198 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Kragballe K, Gjertsen BT, de Hoop D, et al.- Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet, 1991, 337, 193-196.
Cunliffe WJ, Berth-Jones J, Claudy A, et al.- Comparative study of calcipotriol (MC903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol, 1992, 26, 736-743.
Fogh K, Kragballe K.- Vitamin D3 analogues. Dermatol Ther, 1999, 11, 20-31.
Berger U, Wilson P, McClelland RA, et al.- Immunocytochemical detection of 1,25-dyhydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab, 1988, 67, 607-613.
Guyre PM, Girard MT, Morganelli PM, et al.- Glucocorticoid effects on the production and actions of immune cytokines. J Steroid Biochem, 1988, 30, 89-93.
Beato M.- Gene regulation by steroid hormones. Cell, 1989, 56, 335-344.
van de Kerkhof PCM.- Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol, 1995, 132, 675-682.
Barna M, Bos JD, Kapsenberg ML et al.- Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis. Br J Dermatol, 1997, 136, 536-541.
Meltzer EO.- The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy, 1997, 52, 355-363.
van de Kerkhof PCM.- In vivo effects of vitamin D3 analogues. J Dermatol Treat, 1998, 9, S25-S29.
Wissink S, van Heerde EC, van der Burg B et al.- A dual mechanism mediates repression of NF-kappa B activity by glucocorticoids. Mol Endocrinol, 1998, 12, 355-363.
Bury Y, Ruf D, Hansen CM, et al.- Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases. J Invest Dermatol, 2001, 116, 785-792.
Lebwohl M, Siskin SB, Epinette W, et al.- A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol, 1996, 35, 268-269.
Kragballe K, Barnes L, Hambert KJ, et al.- Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol, 1998, 139, 649-654.
Ruzicka T, Lorenz B.- Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol, 1998, 138, 254-258.
Serup J.- Calcipotriol irritation: mechanism, diagnosis and clinical implication. Acta Dermatol Venereol, 1994, 186, S42.
Uhoda I, Quatresooz P, Hermanns-Lê T, et al.- Histometric assessment of psoriatic plaques treated by vitamin D3 derivatives. Dermatology, 2003, 206, 366-369.
Ortonne JP.- Psoriasis: nouvelle modalité thérapeutique par le calcipotriol plus le dipropionate de bétaméthasone. Nouv Dermatol, 1995, 14, 46-51.
Ortonne JP, Kaufmann R, Lecha M et al.- Efficacy of treatment with Calcipotriol/Betamethasone Dipropionate followed by Calcipotriol alone compared with Tacalcitol for the treatment of Psoriasis vulgaris: a randomised, doubled-blind trial. Dermatology, 2004, 209, 308-313
Dumas KJ, Scholtz JR.- The psoriasis bio-assay for topical corticosteroid activity. Acta Dermatol Venereol, 1972, 52, 43-48.
Wolff HH, Kreusch JF, Wilhelm KP et al.- The psoriasis plaque test and topical corticosteroids: evaluation by computerized laser profilometry. In: Korting HC, Maibach HI (eds). Topical glucocorticoids with increased benefit/risk ratio. Curr Probl Dermatol. Basel, Karger 1993, vol 21, pp 107-113.
Piérard GE.- EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol, 1998, 10, 1-11.
Henry F, Fumal I, Piérard GE.- Postural skin colour changes during the corticosteroid blanching assay. Skin Pharmacol Appl Skin Physiol, 1999, 12, 199-210.
Douglas WS, Poulin Y, Decroix J, et al.- A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Dermatol Venereol, 2002, 82, 131-135.
Guenther L, Cambazard F, van de Kerkhof PCM, et al.- Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol, 2002, 147, 316-323.
Kaufmann R, Bibby AJ, Bissonnette R, et al.- A new calcipotriol/ betamethasone dipropionate formulation (Daivobet™) is an effective once daily treatment for psoriasis vulgaris. Dermatology, 2002, 205, 389-393.
Papp KA, Guenther L, Boyden B, et al.- Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol, 2003, 48, 48-54.
Kragballe K, Noerrelund KL, Lui H, et al.- Efficacy of once-daily treatment dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol, 2004, 150, 1167-1173.